Skip to main content
Menu

Cardiology - Monthly Reports

List of monthly reports on Cardiology

Cardiology Research Analysis

April’s cardiology research featured convergent mechanistic and clinical signals with clear translational paths. Highest‑impact findings included reversible sarcomeric dysfunction in obesity‑associated HFpEF, definitive evidence against delaying PCI for LV unloading in non‑shock anterior STEMI, and a decoy strategy targeting ApoB N‑terminal interfaces to block arterial lipoprotein entry. Practice‑informing trials underscored the symptomatic value of CTO PCI in a sham‑controlled design and nomina

Cardiology Research Analysis

Cardiology research in March 2026 advanced practice-defining trials and translational targets. Long-term randomized evidence supports earlier surgery for asymptomatic very severe aortic stenosis, while a placebo-controlled trial of an oral PCSK9 inhibitor achieved potent LDL-C lowering with favorable safety. System-level AI decision support reduced vascular events at scale, and a definitive RCT challenged routine left atrial appendage closure versus optimized medical therapy in high-risk AF. Mec

Cardiology Research Analysis

Cardiology research in February 2026 emphasized scalable care delivery, precision electrophysiology, and device-enabled continuous monitoring. A pragmatic cluster RCT showed community health worker–led hypertension care with mobile decision support improved 12‑month control without safety trade-offs. Translational work identified the sST2–IGF2R–YY1 axis as a driver and prognostic biomarker in fulminant myocarditis, while spatial single‑cell biology informed targeted ablation of nonmyocyte-rich a

Cardiology Research Analysis

January’s cardiology literature converged on five sustained directions: battery-independent pacing via in-situ energy harvesting, open self-supervised ECG foundation models, a validated serum biomarker (NOTCH3‑ECD) for idiopathic PAH, critical reappraisal of HFpEF echocardiographic diastolic grading against invasive hemodynamics, and a translational paradigm linking pressure overload to anthracycline cardiotoxicity. An RCT-level validation of generative AI for low-dose DSA underscores immediate

Cardiology Research Analysis

December cardiology research featured practice-changing interventional studies, precision device guidance, and mechanistic targets that bridge bench to bedside. Two randomized data sets stood out: drug-coated balloons outperformed drug-eluting stents for de novo small-vessel CAD, and 4D CMR-guided lead targeting improved CRT response without procedural penalty. A cardio-oncology study identified endothelial PIEZO1 mechanotransduction as a protective axis against VEGFR-TKI–related injury, while a

Cardiology Research Analysis

November’s cardiology research converged on inflammation and immune‑metabolic mechanisms, precision lipid therapeutics, and practice‑shaping procedural evidence. Multi‑omic studies linked clonal hematopoiesis to a distinct inflammatory proteome and to macrophage pathways driving aortic valve calcification, while an epigenetic enzyme (Hat1) emerged as a regulator of post‑MI inflammatory remodeling. Translational immunology identified bilirubin‑reactive intragraft antibodies as a novel antigenic d

Cardiology Research Analysis

October 2025 cardiology research emphasized translation-ready innovations spanning devices, molecular targets, and genetics. A randomized trial showed a fully biodegradable PFO device is noninferior to nitinol and disappears on imaging by 24 months, signaling a shift in structural device design. Mechanistic studies highlighted neuromodulation via stellate ganglion glia (P2Y1R/IGFBP2), endothelial metabolic protection via bile acid–FXR signaling (TCDCA), and PAI‑1 as a causal mediator of vascular

Cardiology Research Analysis

September’s cardiology literature converged on two themes: immediate practice guidance and mechanism-driven precision. A double-blind NEJM RCT showed net harm from adding aspirin to chronic oral anticoagulation in high-risk chronic coronary syndrome, while a Lancet meta-analysis delivered validated, quantitative rules to calibrate antihypertensive intensity. Translational studies mapped targetable biomechanical and endothelial pathways (ADAMTS1–ITGα8; HEG1–PHACTR1) and identified a cardiomyocyte

Cardiology Research Analysis

August’s cardiology literature highlighted mechanistic cardio-oncology toxicity, non-sarcomeric genetic mechanisms in hypertrophic cardiomyopathy, and blood-based epigenetic risk stratification. A Circulation preclinical study mapped ponatinib’s TNFR2-driven endothelial and thromboinflammatory activation and contrasted it with asciminib’s neutral profile. Independent genetic/epigenetic studies broadened disease frameworks and enabled higher-fidelity prognostics in cardiometabolic care. AI-enable

Cardiology Research Analysis

July’s cardiology literature emphasized precision therapeutics and scalable diagnostics. A network meta-analysis supports sex-specific de-escalation of antiplatelet therapy after PCI, while mechanistic-translational work identified a SIRT1–PCSK9 acetylation axis that preserves LDLR and attenuates atherosclerosis. A large meta-analysis quantified absolute ASCVD prevention benefits of GLP-1 receptor agonists across broad populations. Parallel advances in AI-enabled echocardiography and CMR-first p

Cardiology Research Analysis

June’s cardiology literature converged on physiology-guided care, scalable AI diagnostics, and combination cardiorenal therapy. A national-scale dynamic model for PCI bleeding risk, a multicenter wearable-AI method to noninvasively estimate PCWP, and comprehensive AI echocardiography signal practical, near-term workflow changes. Simultaneous MR antagonism with SGLT2 inhibition (CONFIDENCE) and robust weight loss with a GLP‑1/glucagon dual agonist (mazdutide) highlight therapeutic advances with p

Cardiology Research Analysis

May 2025 cardiology research featured randomized interventional evidence, pragmatic diagnostic protocol upgrades, and translational gene therapy. Extended head-to-carina CTA in acute stroke quintupled cardioaortic thrombus detection without delaying workflow, while epicardial substrate ablation reduced ventricular fibrillation in symptomatic Brugada syndrome. Finerenone’s benefit extended to heart failure with improved ejection fraction, supporting continued neurohormonal therapy after EF recove

Cardiology Research Analysis

April’s cardiology literature coalesced around hypertension control, translational therapeutics, and scalable diagnostics. An individual-patient meta-analysis established ambulatory BP time-in-target (PTTR) as a superior, actionable predictor of mortality and cardiovascular events, while a large cluster RCT showed intensive BP lowering reduced all-cause dementia. Therapeutic innovation spanned aldosterone synthase inhibition (lorundrostat) for resistant hypertension, modified mRNA replacement fo

Cardiology Research Analysis

March 2025 cardiology research converged on translational targets with immediate therapeutic promise and scalable diagnostics. Single-cell/spatial atlases and mechanistic genetics pinpointed druggable pathways in post-MI fibrosis (CD248 stromal checkpoint), endothelial dysfunction (erythrocyte EV–arginase-1), and foam-cell atherogenesis (macrophage HM13/SPP), while common-variant fine-mapping connected epigenetics to endothelin signaling. Large human genomics defined dominant congenital heart di

Cardiology Research Analysis

February’s cardiology literature coalesced around scalable AI diagnostics, procedure-optimizing RCTs, and therapeutics that extend benefits to ischemic outcomes. Dual SGLT1/2 inhibition with sotagliflozin reduced myocardial infarction, stroke, and total MACE in T2D with CKD, while a Circulation RCT (TRAVERSE) showed transseptal LV access halves MRI‑detected brain lesions during ablation. AI advanced on two fronts: direct-to-physician ambulatory ECG reporting that markedly reduces missed critical

Cardiology Research Analysis

January’s cardiology literature featured practice-shaping randomized trials and translational advances. Factor XI inhibition with monthly abelacimab markedly reduced bleeding versus rivaroxaban in atrial fibrillation, while SCOT-HEART’s 10-year data confirmed that CCTA-guided care sustainably lowers non-fatal MI and MACE through optimized prevention. Finerenone reduced new-onset diabetes in HFpEF/HFmrEF, linking HF pharmacotherapy to metabolic risk reduction. Mechanistic and early-translation st